Statins might exert diabetogenic effects, potentially increasing insulin resistance and worsening glucose control. However, patients with diabetes mellitus are at high or very high cardiovascular risk and, thus, statin use is strongly recommended. Adding ezetimibe to statins might be helpful in achieving lipid targets and reducing cardiovascular risk without adversely affecting glucose metabolism.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Mansi, I. A. et al. Association of statin therapy initiation with diabetes progression: a retrospective matched-cohort study. JAMA Intern. Med. https://doi.org/10.1001/jamainternmed.2021.5714 (2021).
Mach, F. et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111–188 (2020).
Wu, H., Shang, H. & Wu, J. Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Endocrine 60, 229–239 (2018).
Cho, Y. et al. Effect of ezetimibe on glucose metabolism and inflammatory markers in adipose tissue. Biomedicines 8, 512 (2020).
Giugliano, R. P. et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 137, 1571–1582 (2018).
de Carvalho, L. S. F., Campos, A. M. & Sposito, A. C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care 41, 364–367 (2018).
Sánchez-García, A., Simental-Mendía, M. & Simental-Mendía, L. E. Effect of proton-pump inhibitors on glucose and insulin metabolism on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Curr. Pharm. Des. 26, 4007–4013 (2020).
Peng, C. C. et al. Effects of proton pump inhibitors on glycemic control and incident diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 106, 3354–3366 (2021).
Wang, K. Y. et al. Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice. Am. J. Pathol. 177, 713–723 (2010).
Katsiki, N., Banach, M. & Mikhailidis, D. P. Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient! Arch. Med. Sci. 15, 1357–1364 (2019).
N.K. has given talks, attended conferences and participated in trials sponsored by Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Novartis, Novo Nordisk, Sanofi, Servier, Viatris and Vianex. D.P.M. has given talks, acted as a consultant or attended conferences sponsored by Amgen and Novo Nordisk.
Rights and permissions
About this article
Cite this article
Katsiki, N., Mikhailidis, D.P. Statins and diabetes mellitus progression: a fly in the ointment?. Nat Rev Endocrinol 18, 137–138 (2022). https://doi.org/10.1038/s41574-021-00612-z